Evidence map›Paper›PMID 33744944›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021

The Initial QuantiFERON-Lyme Prototype is Unsuitable for European Patients.

M E Baarsma, F R van de Schoor, C C Van den Wijngaard, L A B Joosten, Bart Jan Kullberg, Joppe W Hovius

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

M E BaarsmaAmsterdam UMC, University of Amsterdam, Center for Experimental and Molecular Medicine, Amsterdam Institute for Infection and Immunology, Amsterdam, The Netherlands.
F R van de SchoorRadboudumc, Department of Internal Medicine, Radboud Center for Infectious Diseases (RCI) and Radboud Institute of Health Sciences (RIHS), Nijmegen, The Netherlands.
C C Van den WijngaardNational Institute for Public Health and the Environment (RIVM), Center of Infectious Disease Control, Bilthoven, The Netherlands.
L A B JoostenRadboudumc, Department of Internal Medicine, Radboud Center for Infectious Diseases (RCI) and Radboud Institute of Health Sciences (RIHS), Nijmegen, The Netherlands.
Bart Jan KullbergRadboudumc, Department of Internal Medicine, Radboud Center for Infectious Diseases (RCI) and Radboud Institute of Health Sciences (RIHS), Nijmegen, The Netherlands.
Joppe W HoviusAmsterdam UMC, University of Amsterdam, Center for Experimental and Molecular Medicine, Amsterdam Institute for Infection and Immunology, Amsterdam, The Netherlands.

Funding

Netherlands Organization for Health Research and Development 522050001
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Interferon-gamma Release TestsLyme DiseaseAntibodies, BacterialHumansAntibodies, Bacterial

Identifiers

PMID33744944
PMCPMC8522795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.